195 related articles for article (PubMed ID: 10506617)
1. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.
Cullen MH; Billingham LJ; Woodroffe CM; Chetiyawardana AD; Gower NH; Joshi R; Ferry DR; Rudd RM; Spiro SG; Cook JE; Trask C; Bessell E; Connolly CK; Tobias J; Souhami RL
J Clin Oncol; 1999 Oct; 17(10):3188-94. PubMed ID: 10506617
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
[TBL] [Abstract][Full Text] [Related]
3. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).
Booton R; Lorigan P; Anderson H; Baka S; Ashcroft L; Nicolson M; O'Brien M; Dunlop D; O'Byrne K; Laurence V; Snee M; Dark G; Thatcher N
Ann Oncol; 2006 Jul; 17(7):1111-9. PubMed ID: 16603599
[TBL] [Abstract][Full Text] [Related]
4. [Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
Cok G; Göksel T; Soyer S; Atil H; Güzelant A; Aysan T
Tuberk Toraks; 2006; 54(2):161-7. PubMed ID: 16924573
[TBL] [Abstract][Full Text] [Related]
5. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
Berghmans T; Lafitte JJ; Thiriaux J; VanHoutte P; Lecomte J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Mommen P; Ninane V; Sculier JP;
Lung Cancer; 2004 Sep; 45(3):339-48. PubMed ID: 15301874
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
Rudd RM; Gower NH; Spiro SG; Eisen TG; Harper PG; Littler JA; Hatton M; Johnson PW; Martin WM; Rankin EM; James LE; Gregory WM; Qian W; Lee SM
J Clin Oncol; 2005 Jan; 23(1):142-53. PubMed ID: 15625369
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
Crinò L; Scagliotti GV; Ricci S; De Marinis F; Rinaldi M; Gridelli C; Ceribelli A; Bianco R; Marangolo M; Di Costanzo F; Sassi M; Barni S; Ravaioli A; Adamo V; Portalone L; Cruciani G; Masotti A; Ferrara G; Gozzelino F; Tonato M
J Clin Oncol; 1999 Nov; 17(11):3522-30. PubMed ID: 10550150
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer.
Rosell R; Maestre J; Font A; Moreno I; Molina F; Milla A; Gómez-Codina J; Camps C
Semin Oncol; 1994 Jun; 21(3 Suppl 4):28-33. PubMed ID: 8209274
[TBL] [Abstract][Full Text] [Related]
9. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.
Smith IE; O'Brien ME; Talbot DC; Nicolson MC; Mansi JL; Hickish TF; Norton A; Ashley S
J Clin Oncol; 2001 Mar; 19(5):1336-43. PubMed ID: 11230476
[TBL] [Abstract][Full Text] [Related]
10. Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC).
Han JY; Kim HK; Choi BG; Moon H; Hong YS; Lee KS
Jpn J Clin Oncol; 1998 Dec; 28(12):749-53. PubMed ID: 9879293
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.
Furuse K; Fukuoka M; Kawahara M; Nishikawa H; Takada Y; Kudoh S; Katagami N; Ariyoshi Y
J Clin Oncol; 1999 Sep; 17(9):2692-9. PubMed ID: 10561343
[TBL] [Abstract][Full Text] [Related]
12. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.
Depierre A; Milleron B; Moro-Sibilot D; Chevret S; Quoix E; Lebeau B; Braun D; Breton JL; Lemarié E; Gouva S; Paillot N; Bréchot JM; Janicot H; Lebas FX; Terrioux P; Clavier J; Foucher P; Monchâtre M; Coëtmeur D; Level MC; Leclerc P; Blanchon F; Rodier JM; Thiberville L; Villeneuve A; Westeel V; Chastang C;
J Clin Oncol; 2002 Jan; 20(1):247-53. PubMed ID: 11773176
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide containing regimen for non-small cell lung cancer.
Behera D; Aggarwal AN; Sharma SC; Gupta D; Jindal SK
Indian J Chest Dis Allied Sci; 2004; 46(1):9-15. PubMed ID: 14870863
[TBL] [Abstract][Full Text] [Related]
14. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
Westeel V; Quoix E; Moro-Sibilot D; Mercier M; Breton JL; Debieuvre D; Richard P; Haller MA; Milleron B; Herman D; Level MC; Lebas FX; Puyraveau M; Depierre A;
J Natl Cancer Inst; 2005 Apr; 97(7):499-506. PubMed ID: 15812075
[TBL] [Abstract][Full Text] [Related]
15. Trials with mitomycin, ifosfamide and cisplatin in non-small cell lung cancer.
Cullen MH
Lung Cancer; 1995 Apr; 12 Suppl 1():S95-106. PubMed ID: 7551939
[TBL] [Abstract][Full Text] [Related]
16. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer.
Kubota K; Furuse K; Kawahara M; Kodama N; Yamamoto M; Ogawara M; Negoro S; Masuda N; Takada M; Matsui K
J Clin Oncol; 1994 Aug; 12(8):1547-52. PubMed ID: 8040666
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer.
Stephens RJ; Girling DJ; Hopwood P; Thatcher N;
Lung Cancer; 2005 Sep; 49(3):395-400. PubMed ID: 15908042
[TBL] [Abstract][Full Text] [Related]
18. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
Bonomi P; Kim K; Fairclough D; Cella D; Kugler J; Rowinsky E; Jiroutek M; Johnson D
J Clin Oncol; 2000 Feb; 18(3):623-31. PubMed ID: 10653877
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Crinò L; Clerici M; Figoli F; Carlini P; Ceci G; Cortesi E; Carpi A; Santini A; Di Costanzo F; Boni C
Ann Oncol; 1995 Apr; 6(4):347-53. PubMed ID: 7619749
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin.
González Barón M; Artal A; Garrido P; García Girón C; Ordóñez A; Feliu J; Berrocal A; Barón JM
Am J Clin Oncol; 1993 Aug; 16(4):310-4. PubMed ID: 8392287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
